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ABSTRACT
Objective: A simple, specific, accurate, and precise method, namely, reverse phase high-performance liquid chromatography was to develop for 
simultaneous estimation of Lidocaine (LDC) and prilocaine (PLC) in a topical local anesthetic cream.
Method: The mixture of PLC and LDC was separated on Hi Q Sil C18 HS column, (250 mm × 4.6 mm, 5 μm), column temperature ambient and flow 
rate 1.2 mL/minutes. The mobile phase was acetonitrile: 0.01 M diethylamine solution (pH adjusts to 6.8 with orthophosphoric acid) (60:40) with 
detection at 225 nm.
Results: The retention time was found to be 6.075±0.12 minutes for PLC and 8.642±0.15 minutes for LDC, respectively. Linearity was observed 
in the concentration range of 1-6 μg/mL for both LDC and PLC, respectively. The method was validated according to International Conference on 
Harmonization guideline and values of linearity, precision, robustness, limit of detection, limit of quantitation, selectivity, and recovery were found to 
be in good accordance with the prescribed value.
Conclusion: The proposed method can be useful in the quality control of LDC and PLC in their topical formulation.
Keywords: High-performance liquid chromatography, Prilocaine, Lidocaine, Validation.
INTRODUCTION
Lidocaine (LDC) is a local anesthetic which acts by causing blockade 
of sodium channel that leads to decrease in sodium conductance and 
depresses the rate of electrical depolarization; then, threshold potential 
level and propagation of action potential failure are achieved which 
ultimately leads to blockade of conduction in case of local anesthetic. LDC, 
chemically is 2-(diethylamino)-N-(2, 6-dimethylphenyl) acetamide [1]. 
Prilocaine (PLC) is an amide local anesthetic with pharmacological 
properties similar to lignocaine. To increase the duration of action 
and delay uptake by the general circulation local anesthetics may be 
administered with a vasoconstrictor, usually adrenaline. Chemically, 
PLC is (RS)-N-(2-Methylphenyl)-2-(propylamino) propanamide. 
PLC, unlike otheramide anesthetics, is a secondary amino derivative 
oftoludine. It produces less vasodilation and toxicitythan LDC and is 
considered relatively free from an allergic reaction [2,3]. The chemical 
structures of PLC and LDC are shown in (Fig. 1).
To determine PLC and LDC, many studies have been reported in 
literature. Several spectrophotometric [4-6], chromatographic [7-18], 
liquid chromatography-tandem mass spectrometry [19-21], and 
gas chromatography-mass spectrometry [22-24] and capillary 
electrophoresis [25] techniques were developed to determine PLC and 
LDC in both pharmaceutical preparations and human plasma. The aim 
of the present work is to develop and validate a new high-performance 
liquid chromatography (HPLC) method for determination of PLC and 
LDC in topical formulation. The proposed method was validated with 
validation parameters, which are sensitivity, specificity, linearity, 
precision, and accuracy in accordance with International Conference 
on Harmonization (ICH) guidelines [26].
METHODS
Chemicals and reagents
Pure LDC and PLC were kindly gifted by Neon Labs Pvt., Ltd., (Thane), 
Mumbai, India. Commercial LDC (2.5%) and PLC (2.5%) topical local 
anesthetic cream were purchased from local market for the study. 
Acetonitrile (ACN) used of HPLC grade (S.K Enterprises, Pune, India). 
Double distilled water used in experiment was obtained from Milli-Q 
system (Millipore).
Instrumentation and chromatographic conditions
The HPLC system consisted of intelligent HPLC pump model (Jasco 
PU 2080 Plus) with sampler programmed at 20 μL capacity per 
injection was used. The detector consisted of an ultraviolet (UV)-visible 
spectrophotometry (Jasco UV 2075 Plus). Data were integrated using 
Jasco Borwin version 1.5, LC-Net II/ADC system. Chromatographic 
separation was carried out with HiQSilHSC18column (250 mm × 
4.6 mm, 5 µm). The mobile phase used for isocratic elution was 
prepared by mixing ACN: 0.01M diethylamine solution (pH adjusts to 
6.8 with orthophosphoric acid) (60:40 v/v). Before use, the mobile 
phase was filter through 0.45 μm membrane filter and degassed by 
ultrasonication. The flow rate was 1.2 mL/minutes, column temperature 
25°C, the injection volume was 20 μL, and detection was performed at 
225 nm using a UV detector.
Preparation of standard stock solutions
The standard stock solutions of LDC and PLC were prepared by 
accurately weighing 10 mg of each drug into a 10 mL volumetric 
flask. The drugs were dissolved in methanol and the solution was 
diluted to volume. Further dilutions were made from this stock 
solution and the injection volume was kept 20 μL. A calibration 
curve was plotted between concentration against their respective 
area for LDC and PLC separately. From the calibration curve, it was 
found that linearity ranges for both drugs 1-6 μg/mL for LDC and 
PLC, respectively.
Analysis of marketed formulation
To determine, the content of LDC and PLC in marketed topical 
formulation (LDC 2.5% and PLC 2.5% cream). A portion of the cream 
preparation (1 gm equivalent to 25 mg LDC and 25 mg PLC) was weighed 
© 2017 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
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and extracted into 15 mL methanol with the aid of ultrasonication for 
15 minutes then filtered into a 25 mL volumetric flask. The volume was 
made with methanol. From the above solution, further dilution was 




The HPLC procedure was optimized for simultaneous determination 
of PLC and LDC. Good resolution of both components was obtained 
with ACN: 0.01 M diethylamine solution (pH adjusts to 6.8 with 
orthophosphoric acid) at ratio 60:40 v/v. The flow rate of 1.2 mL/minutes 
was optimum. UV detection was made at 225 nm. At this wavelength, 
PLC and LDC can be quantified. Hence, 225 nm determined empirically 
has been found to be optimum. The average retention times for PLC and 
LDC was found to be 6.075 and 8.642 minutes, respectively (Fig. 2). The 
system suitability parameters for HPLC chromatogram are as follows 
(Table 1).
Linearity and range
Linearity is generally evaluated by visual inspection of a plot of signals 
as a function of analyte concentration or content. For determining 
linearity, calibration curves were plotted over a concentration range 
of 1-6 μg/mL for PLC and 1-6 μg/mL for LDC, respectively. A 20 μL 
of sample solution was injected into the chromatographic system 
using fixed volume loop injector. Chromatograms were recorded. All 
measurements were repeated three times for each concentration and 
calibration curve was constructed by plotting the peak areas of analyte 
versus the corresponding drug concentration.
Linear regression data for the calibration plots revealed good linear 
relationships between response and concentration. The linear 
regression equations were Y=24047X+24844 (r2=0.9994) for PLC and 
Y=31596X+13687 (r2=0.9991) for LDC. The plots obtained from linear 
regression are given in (Fig. 3) for PLC and (Fig. 4) for LDC, respectively.
 Limits of detection and quantitation
The limit of detection (LOD) and limit of quantification (LOQ) were 
calculated according to the 3.3 σ/s and 10 σ/s criteria, respectively, 
where σ is the standard deviation of the peak area and s is the slope 
of the corresponding calibration curve. The LOD and the LOQ for HPLC 
were found to be 0.2 μg/mL and 0.6 μg/mL for PLC and 0.3 μg/mL and 
0.8 μg/mL for LDC, respectively.
Precision
The precision of the proposed method was assessed as intraday and 
interday precision by preparing three different sample solutions at 
low, medium, and high concentrations, which were freshly prepared 
and analyzed. The intraday precision % relative standard deviation 
(% RSD) was assessed by analyzing standard drug solutions within 
the calibration range, three times on the same day. Interday precision 
RSD% was assessed by analyzing drug solutions within the calibration 
range on three different days over a period of a week. The precision of 
the method was expressed as RSD%. The results showed in (Table 2) 
shows the high precision of the method.
Accuracy
The difference between theoretical added amount and practically 
achieved amount is called accuracy of analytical method. To check the 
Table 1: System suitability parameters
Parameter PLC LDC
Retention time (minutes) 6.075 8.642
Resolution (Rs) - 7.068
Theoretical plates number (N) 6246 5689
Tailing factor 1.21 1.19
PLC: Prilocaine, LDC: Lidocaine
Fig. 2: Chromatogram of Prilocaine and Lidocaine
Fig. 3: Calibration curve for Prilocaine
Fig. 4: Calibration curve for Lidocaine
Fig. 1: Chemical structures of (a) Prilocaine, and (b) Lidocaine
ba
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degree of accuracy of the method, recovery studies were performed 
in triplicate by standard addition method at 80%, 100%, and 120%. 
Known amount of standard PLC and LDC were added to pre-analyzed 
samples and were subjected to the proposed method. Result of recovery 
study of HPLC method is shown in (Table 3).
Robustness
Robustness was assessed by deliberately changing the 
chromatographic conditions and studying the effects on the results 
obtained. The factor chosen for study were the flow rate, mobile 
phase composition, and pH. In the above-changed conditions, results 
of robustness studies were expressed in term of % RSD of peak 
areas in each changed condition and were compared with similar 
results obtained in unchanged experimental conditions. The method 
was found to be unaffected by small changes with % RSD for all the 
parameters <2% indicating that method is robust. Result of robustness 
study is shown in Table 4.
Analysis of marketed formulation
When the LDC (2.5%) and PLC (2.5%) cream was analyzed by HPLC, 
sharp and well-defined peaks for PLC and LDC were obtained at Rt 
6.075 and 8.642 minutes, respectively, when scanned at 225 nm. The 
amount of the label claim measured was 99.89% for PLC and 99.78% 
for LDC, respectively.
CONCLUSION
The proposed reverse phase (RP)-HPLC method has been developed for 
the simultaneous analysis of PLC and LDC in their topical formulation. 
The method was validated as per ICH guidelines. The validation results 
reveal that the methods are precise, linear, robust, and accurate, which 
proves the reliability of the proposed method. The HPLC method can be 
used for routine quality control analysis of PLC and LDC in their topical 
cream formulation.
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